David Kolesky
Principal MPM Capital
Dr. David Kolesky is a Principal at MPM BioImpact. He is responsible for driving investments and company creation activities.
Before joining MPM BioImpact, David was a Principal at Flagship Pioneering, where he focused on conceiving, creating, and operating new bioplatform technology companies. David co-founded and helped launch several companies, notably Senda Biosciences and Montai Health, where he held key leadership roles at early stages of development including Chief Scientific Officer and Chief Innovation Officer at Montai, and Head of Platform at Senda. David has developed a wide range of scientific and technical experience by working across diverse platforms, including AI-enabled small molecule discovery, programmable delivery of genomic medicines, and cell & tissue engineering.
David received his Ph.D. in Engineering Sciences from Harvard University and conducted a postdoctoral fellowship at the Wyss Institute for Biologically Inspired Engineering. Working with Professor Jennifer Lewis at Harvard, he invented various technologies for creating vascularized kidney tissues for drug screening and tissue replacement. His work has been published in top journals and he is co-inventor of several issued patents. David has received numerous awards, including the National Inventor’s Hall of Fame Collegiate Inventor Prize.
A native of South Florida, David received his B.S in Materials Science and Engineering from the University of Florida.
Seminars
The biopharmaceutical sector continues to seek new opportunities to leverage mRNA technology and thrives on strategic alliances, which allow for cross-functional sharing of knowledge, skills, and experience across different disciplines to truly advance mRNA drugs to patients faster. Hear first-hand how biopharma business development leaders and investors are taking their time to evaluate novel innovations and building new collaborations.
- Leveraging the past experiences of recent deals, collaborations and acquisitions in mRNA-LNP platforms to inform future risk and decision-making strategies
- Where do you see potential white spaces that mRNA can fill within this sector or indications more specifically?
- What data is required and how far does an asset have to progress towards future investment or acquisition success?
